JENNIFER YUI M.D.
Prescription History 1760898043
Internal Medicine - Hematology in Baltimore, MD


Quality Rating: 74.39 out of 100 score

NPI Status: Active since July 07, 2014

Contact Information

600 N WOLFE ST BLDG 77110A
BALTIMORE, MD
ZIP 21287
Phone: (443) 287-4675
Fax: (410) 614-8601

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JENNIFER YUI M.D., an active Hematology specialist practicing in Baltimore, MD. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 726 documented patient claims. Among these therapy options, the most frequently utilized medication is Warfarin Sodium, which accounts for 564 claims alone.

Medication Index


Besremi

Generic Formulation: Ropeginterferon Alfa-2b-NjftSpecialty: Hematology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 392
MD State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills21.7
Peer Average Days Supply541
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $209,717.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,979.85

State Avg Cost Per Claim

$12,997.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Ropeginterferon alfa-2b is used to treat a certain type of cancer (polycythemia vera). This medication is the same as a protein that your body naturally produces (interferon). In the body, it is thought to work by affecting cell function/growth and the body's natural defenses (immune system) in many ways.

Enoxaparin Sodium

Generic Formulation: Enoxaparin SodiumSpecialty: Hematology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 245
MD State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.2
Peer Average Days Supply317
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,214.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$139.75

State Avg Cost Per Claim

$160.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Enoxaparin is used to prevent and treat harmful blood clots. This helps to reduce the risk of a stroke or heart attack. This medication helps keep your blood flowing smoothly by lowering the activity of clotting proteins in the blood. Enoxaparin is an anticoagulant, also known as a blood thinner. It is a type of heparin. Conditions which increase your risk of developing blood clots include certain types of surgeries (such as knee/hip replacement, abdominal), long periods of being immobile, certain types of heart attack, and a specific type of chest pain called unstable angina. For some medical conditions, enoxaparin may be used in combination with other blood thinners.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Hematology
Provider Metrics Summary
Total Claims 14
30-Day Fills 32.7
Days Supply 965
MD State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills54.4
Peer Average Days Supply1,613
Conservative Utilization

This provider writes prescriptions for this formulation 48.1% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $536.03 across this reporting matrix range.

Provider Avg Cost Per Claim

$38.29

State Avg Cost Per Claim

$38.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
MD State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.2
Peer Average Days Supply632
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $222,891.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$17,145.53

State Avg Cost Per Claim

$17,580.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Jantoven

Generic Formulation: Warfarin SodiumSpecialty: Hematology
Provider Metrics Summary
Total Claims 76
30-Day Fills 202.7
Days Supply 6,075
MD State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills68.5
Peer Average Days Supply2,047
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 192.3% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,510.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$19.88

State Avg Cost Per Claim

$17.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Pegasys

Generic Formulation: Peginterferon Alfa-2aSpecialty: Hematology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 308
MD State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.9
Peer Average Days Supply364
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $49,732.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,521.16

State Avg Cost Per Claim

$3,886.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Peginterferon alfa-2a is used alone or in combination with other medications to treat chronic hepatitis B and chronic hepatitis C, viral infections of the liver. It works by decreasing the amount of hepatitis virus in the body and helps your body's natural defense (immune system) fight the infection. Chronic hepatitis infection can lead to serious liver damage (cirrhosis) and liver cancer. It is not known if peginterferon can cure hepatitis B or hepatitis C infections or can prevent you from passing the virus to others. Practice safer sex (such as the use of latex condoms) to lower the risk of passing the virus to others.

Promacta

Generic Formulation: Eltrombopag OlamineSpecialty: Hematology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
MD State Average Benchmarks
Peer Average Claims15.0
Peer Average 30-Day Fills15.6
Peer Average Days Supply457
Conservative Utilization

This provider writes prescriptions for this formulation 26.7% less frequently than the standard regional baseline metric for practitioners inside MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $166,284.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,116.78

State Avg Cost Per Claim

$12,509.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Warfarin Sodium

Generic Formulation: Warfarin SodiumSpecialty: Hematology
Provider Metrics Summary
Total Claims 564
30-Day Fills 1,323.0
Days Supply 39,490
MD State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills89.8
Peer Average Days Supply2,524
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 1,242.9% higher than the standard regional baseline profile for MD. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,222.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.13

State Avg Cost Per Claim

$14.37

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JENNIFER YUI M.D. provides transparency into local medical care patterns within Baltimore, MD.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.